This article discusses a study that examined the effects of empagliflozin and fenofibrate therapies, both individually and in combination, on serum urate concentration in individuals with hyperuricaemic type 2 diabetes. The study found that both therapies led to a reduction in serum urate concentration, with the combination therapy resulting in a greater reduction compared to empagliflozin alone. The study also noted that the treatments were well-tolerated by participants, with only minor side effects reported. These findings suggest that these medications could be effective in managing hyperuricaemia in individuals with type 2 diabetes. However, the combination therapy was associated with a significant reduction in estimated glomerular filtration rate (eGFR), which may have clinical implications. Close monitoring of renal function is recommended when using combination therapy. Overall, the study suggests that combining empagliflozin and fenofibrate could simplify treatment for gout in individuals with diabetes. [Extracted from the article]